Advaxis to begin Phase I/II combination prostate cancer trial of ADXS-PSA and Keytruda

US-based biotechnology firm Advaxis has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application to start a Phase I/II clinical trial to evaluate the combination of ADXS-PSA (ADXS31-142) wit…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news